Literature DB >> 30616873

Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases.

Yongde Luo1, Sheng Ye2, Xiaokun Li3, Weiqin Lu4.   

Abstract

Endocrine fibroblast growth factors (eFGFs) control pathways that are crucial for maintaining metabolic homeostasis of lipids, glucose, energy, bile acids, and minerals. Unlike the heparin-binding paracrine FGFs, eFGFs require a unique Klotho family protein to form a productive triad complex, but the structural and mechanistical details of this complex have remained obscure since the beginning of the eFGF field. However, recent breakthroughs in resolving the 3D structures of eFGF signaling complexes have now unveiled the atomic details of multivalent interactions among eFGF, FGFR, and Klotho. We provide here a timely review on the architecture and the structure-function relationships of these complexes, and highlight how the structural knowledge opens a new door to structure-based drug design against a repertoire of eFGF-associated metabolic diseases.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D structure; FGF21; FGF23; FGFR tyrosine kinase; Klotho; metabolic diseases

Mesh:

Substances:

Year:  2019        PMID: 30616873     DOI: 10.1016/j.tips.2018.12.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  10 in total

1.  The fibroblast growth factor receptor antagonist SSR128129E inhibits fat accumulation via suppressing adipogenesis in mice.

Authors:  Xinzhi Zhang; Xin Wen; Geng Hu; Qiang Zhang; Qianying Sun; Yanxin Jia; Yan Liu; Hai Lin; Haifang Li
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

Review 2.  The Role of Fibroblast Growth Factor 19 Subfamily in Different Populations Suffering From Osteoporosis.

Authors:  Xiawen Yu; Yue Xia; Jue Jia; Guoyue Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

Review 3.  FGF21 in obesity and cancer: New insights.

Authors:  Weiqin Lu; Xiaokun Li; Yongde Luo
Journal:  Cancer Lett       Date:  2020-11-29       Impact factor: 8.679

Review 4.  Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Authors:  Marta Latko; Aleksandra Czyrek; Natalia Porębska; Marika Kucińska; Jacek Otlewski; Małgorzata Zakrzewska; Łukasz Opaliński
Journal:  Cells       Date:  2019-05-14       Impact factor: 6.600

5.  SHBG141-161 Domain-Peptide Stimulates GPRC6A-Mediated Response in Leydig and β-Langerhans cell lines.

Authors:  Luca De Toni; Diego Guidolin; Vincenzo De Filippis; Daniele Peterle; Maria Santa Rocca; Andrea Di Nisio; Maurizio De Rocco Ponce; Carlo Foresta
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

Review 6.  Roles of the fibroblast growth factor signal transduction system in tissue injury repair.

Authors:  Keyang Chen; Zhiheng Rao; Siyang Dong; Yajing Chen; Xulan Wang; Yongde Luo; Fanghua Gong; Xiaokun Li
Journal:  Burns Trauma       Date:  2022-03-23

7.  The effect of different weight loss strategies to treat non-alcoholic fatty liver disease focusing on fibroblast growth factor 21.

Authors:  Nicole Power Guerra; Katharina Leyens; Luisa Müller; David Brauer; Deborah Janowitz; Samin Schlick; Kristin Pilz; Hans J Grabe; Brigitte Vollmar; Angela Kuhla
Journal:  Front Nutr       Date:  2022-08-10

Review 8.  Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases.

Authors:  Sabrina Azevedo Machado; Gabriel Pasquarelli-do-Nascimento; Debora Santos da Silva; Gabriel Ribeiro Farias; Igor de Oliveira Santos; Luana Borges Baptista; Kelly Grace Magalhães
Journal:  Nutr Metab (Lond)       Date:  2022-09-06       Impact factor: 4.654

Review 9.  The FGF metabolic axis.

Authors:  Xiaokun Li
Journal:  Front Med       Date:  2019-09-07       Impact factor: 4.592

Review 10.  Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges.

Authors:  Úrsula Martínez-Garza; Daniel Torres-Oteros; Alex Yarritu-Gallego; Pedro F Marrero; Diego Haro; Joana Relat
Journal:  Int J Mol Sci       Date:  2019-09-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.